Drugs & FDA
93 stories · Page 2 of 4
Gaming a Cancer Trial Is 'Cheap and Easy,' Says a Former Top FDA Official
Vinay Prasad says nobody needs AI to fake a phase 3 cancer win, and a Mayo Clinic audit found 16 of 96 FDA cancer approvals rested on control arms its authors judged suboptimal.
Drugs & FDAThe FDA's Former Biologics Chief Says Public Health Can't See the Next Disaster Coming
Vinay Prasad ran the FDA's biologics center until this spring. His warning: the apparatus chases lettuce recalls and measles while a blood test for dozens of cancers heads toward Medicare with its central question unanswered.
Drugs & FDAFederal Agents Seized Counterfeit Ozempic and Warned the Public. Prosecutors Say the Smuggling Kept Going for Months.
The counterfeits came from China with fake needles and packaging and sold to distributors at a discount. The indictment says the alleged scheme kept running for months after the FDA had already seized counterfeit Ozempic and warned the country.
Drugs & FDAOne Hormone Starves the Brain and Floods the Heart: The FDA's First MCT8 Drug Treats Only the Flood
Emcitate is being called the first treatment for MCT8 deficiency, but its FDA label covers the racing heart and the wasting body, not the brain disability that defines the disease.
Drugs & FDATrump's FDA Nominee Backed Cutting the Vaccine Schedule, Then Hid Behind 'Safe and Effective' Under Oath
Heidi Overton stood beside Trump as he cut the childhood vaccine schedule from 18 diseases to 11. At her confirmation hearing she spent two hours calling every FDA-approved vaccine 'safe and effective' and refused to defend the reform she coordinated.
Drugs & FDAThe FDA's New Fast Lane for Experimental Drugs Is Run by a Lawyer Who Defended the Food and Tobacco Industries
Operation TrialBlazer lets drug sponsors feed their first-in-human safety data to the FDA in pieces, on a rolling clock, to shave months off the wait. The review it speeds is the one that decides whether an untested drug can go into a person at all.
Drugs & FDAThe FDA Warned a Generation Off Hormones. A Danish Registry Puts the Clot Risk in the Pill, Not the Patch.
Oral hormone therapy was tied to more clots, and to strokes and heart attacks at higher doses taken longer. The patches and gels carried no general increase. The warning that scared a generation of women off never drew the line.
Drugs & FDANo FDA-Approved Drug Stops Preterm Labor: a Vanderbilt Screen of All 1,191 Approved Drugs Landed on an Asthma Steroid
Every drug used to halt preterm contractions is borrowed off-label; the FDA has never approved one for the job. A Vanderbilt team screened all 1,191 approved drugs and landed on an asthma steroid.
Drugs & FDAFour Years After Congress Dropped the Animal-Testing Requirement for New Drugs, the FDA Finally Updated Its Rulebook to Match
The FDA's direct final rule swaps 'animal studies' for 'nonclinical studies' across its regulations. It eliminates no animal testing, moves no evidentiary bar, and sets up no program to prove the alternatives it now invites actually work.
Drugs & FDAThe FDA Approved a $3.95 Million Gene Therapy It Rejected Fourteen Months Ago
In July 2025 the FDA refused to approve this Sanfilippo gene therapy and faulted the factory, not the science. Fourteen months later it is the first treatment for a fatal childhood brain disease, cleared on 17 treated children against a comparison group the maker built, at $3.95 million a dose.
Drugs & FDAThe Data on the First Sanfilippo Gene Therapy Were Ready Last Summer. The FDA Spent the Next Year on the Factory.
The FDA said Ultragenyx's clinical data were robust in July 2025, then rejected its Sanfilippo gene therapy over manufacturing questions. Approval came fourteen months later, for children who lose skills and die on a clock.
Drugs & FDATwenty Years, Four Botanical Drugs: The FDA Wants to Know What's Blocking the Rest
Four botanical drugs in two decades, under a framework built for single molecules. Now, inside RFK Jr.'s HHS, the agency that wrote those rules is asking what blocked the rest, and whether it means it.
Drugs & FDAThe FDA's New Pilot Lets a Drug Sponsor Choose the Institution Helping Build Its First-in-Human Application, and Reviews the Pieces as They Arrive
The agency will select 8 to 10 sponsor-QRI pairs to co-develop first-in-human trial applications it reviews on a rolling basis, and its stated reason is that China and Australia get there faster.
Drugs & FDAA Fatal Brain Disease in Children Finally Has a Drug, and It Lists at $1.14 Million a Year
Ionis's zilganersen is the first therapy ever approved for Alexander disease, and it lists near $1.14 million a year. The same FDA approval handed Ionis a rare pediatric disease voucher, the transferable coupon that has resold for as much as $350 million.
Drugs & FDAThe FDA Approved a Breast Cancer Drug Its Own Advisers Had Just Rejected, 6 to 3
An FDA advisory panel voted 6 to 3 that AstraZeneca had not shown its breast cancer drug delivered a meaningful benefit. The agency approved it four months later anyway.
Drugs & FDASickle Cell Finally Has a Cure. It Costs $2.2 Million and Has Reached 64 People.
Casgevy has kept Victoria Gray crisis-free for seven years. Getting it still means wiping out a patient's bone marrow with a chemo tied to infertility and malignancy warnings and paying about $3 million all in, and two years after approval only 64 people have been infused.
Drugs & FDAThe 'Bone-Building Switch' Is Back in the Headlines. It Was Tested in Mice, and Only Mice
A publicly funded Leipzig compound rebuilt bone in ovariectomized mice, 8 per treated group. More than a year later the same experiment is still being sold to readers as a way to keep their bones strong for life.
Drugs & FDATwo Factories Make the Starter IV Nutrition America's Preemies Live On. Both Are Closing, and the Backup Plan Has Killed Babies Before.
The predominant source of starter IV nutrition for premature newborns is two outsourcing facilities, and both are permanently closing. The FDA's fix: let hospital pharmacies mix it themselves for 180 days, sending the most unforgiving product in medicine back into the loosely regulated compounding t
Drugs & FDAThe FDA Has Approved 4 Plant Drugs Since 2004. Now It's Asking the Public Why So Few Made It.
A request for public input is not reform. After two decades of a pathway that produced four approvals, the question is whether the agency wants plant medicine or just wants to talk about it.
Drugs & FDAIonis Priced the First Alexander Disease Drug at $1.14 Million a Year, and Got a Federal Voucher It Can Resell for More Than $100 Million
Zilganersen is the first drug for Alexander disease, an antisense therapy designed to lower the toxic protein that drives a fatal brain disease. It also carries a $1.14 million annual price and a pediatric voucher Ionis can resell for more than $100 million.
Drugs & FDAThe FDA Approved a Breast Cancer Drug Four Months After Its Advisers Voted No
On April 30 the FDA's oncology advisers voted 6 to 3 that AstraZeneca's camizestrant hadn't shown a clinically meaningful benefit. On September 4 the agency approved it anyway, conceding in its own approval that the benefit is "not yet confirmed."
Drugs & FDAChina Runs More Drug Trials Than America. The FDA Says It Can No Longer Trust Data From Sites It Can't Inspect.
China went from under 8 percent of the world's drug trials in 2010 to passing the United States by 2020. After three deaths in Chinese studies surfaced late, the FDA says it has sometimes been denied access to the very sites whose data underpins American approvals.
Drugs & FDAThe Pancreatic-Cancer Pill That Doubles Survival: $39,800 a Month, and a Fast Lane Congress Never Approved
Rasonque roughly doubles median survival in metastatic pancreatic cancer. Revolution Medicines priced it at $477,600 a year, more than double Keytruda, and the FDA cleared it early through a voucher program lawmakers say Congress never authorized.
Drugs & FDAA Pill Doubled Survival in Advanced Pancreatic Cancer: Six Months to Thirteen, at $39,800 a Month
The best result advanced pancreatic cancer has seen in a generation, and the FDA cleared it in about five weeks. For patients who have run out of chemo, it turns a median of six months into thirteen, at a list price of $39,800 a month.